Associations between atherogenic index of plasma, Alzheimer’s biomarkers, and the risk of cognitive impairment: Hubei Memory and Aging Cohort Study

INTRODUCTION: The atherogenic index of plasma (AIP) is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment in older adults is limited. We examined whether AIP was associated with incident cognitive impairment, and explored associations with plasma Alzheimer's disease (AD) biomarkers and apolipoprotein E (APOE) ε4 status. METHODS: This study included 1,143 adults aged ≥ 65 years from the Hubei Memory and Aging Cohort Study. AIP was calculated as log(triglyceride/high-density lipoprotein cholesterol). The association of AIP with incident cognitive impairment and its joint effects with plasma AD biomarkers were evaluated using Cox models. Dose-response associations were assessed by restricted cubic splines. Cognitive domain declines were analyzed using linear mixed-effects models. Analyses were stratified by APOE ε4 status. RESULTS: After adjustment, higher baseline AIP was independently associated with greater risk of cognitive impairment, showing a nonlinear dose-response relationship (inflection point: 0.758). Compared to the lowest quartile, the highest quartile exhibited a higher risk (Hazard Ratio [HR] = 2.15; 95% Confidence Interval [CI]: 1.47-3.12). Higher AIP also correlated with faster memory decline (β = -0.14, 95% CI: -0.26 to -0.01). Participants with higher AIP and elevated p-tau181 had an increased risk of cognitive impairment (HR = 3.46, 95% CI: 1.58-7.61). These effects were more pronounced among APOE ε4 carriers. CONCLUSIONS: Higher AIP was associated with cognitive impairment and faster memory decline. High AIP combined with elevated p-tau181 was associated with greater risk, particularly among APOE ε4 carriers, supporting refined risk stratification in older adults.

Authors

Publication Details

Journal
Neuroepidemiology
Published
2026-11-18
DOI
https://doi.org/10.1159/ned/adwag072
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Associations between atherogenic index of plasma, Alzheimer’s biomarkers, and the risk of cognitive impairment: Hubei Memory and Aging Cohort Study

程桂荣, Xiaochang Liu, 雅史 田, Xinyi Deng et al.
9 links
Neuroepidemiology
Dementia and Cognitive Impairment Research
article

Associations between atherogenic index of plasma, Alzheimer’s biomarkers, and the risk of cognitive impairment: Hubei Memory and Aging Cohort Study

程桂荣, Xiaochang Liu, 雅史 田, Xinyi Deng, Xiaobo Liu, Yan Zeng, Xinyan Xie, Qidi Tang, Ming Ouyang, Long Chen, Mengru Fu, Feifei Hu, Dan Liu, Yanling Zhou, Lang Xu
article en

Abstract

INTRODUCTION: The atherogenic index of plasma (AIP) is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment in older adults is limited. We examined whether AIP was associated with incident cognitive impairment, and explored associations with plasma Alzheimer's disease (AD) biomarkers and apolipoprotein E (APOE) ε4 status. METHODS: This study included 1,143 adults aged ≥ 65 years from the Hubei Memory and Aging Cohort Study. AIP was calculated as log(triglyceride/high-density lipoprotein cholesterol). The association of AIP with incident cognitive impairment and its joint effects with plasma AD biomarkers were evaluated using Cox models. Dose-response associations were assessed by restricted cubic splines. Cognitive domain declines were analyzed using linear mixed-effects models. Analyses were stratified by APOE ε4 status. RESULTS: After adjustment, higher baseline AIP was independently associated with greater risk of cognitive impairment, showing a nonlinear dose-response relationship (inflection point: 0.758). Compared to the lowest quartile, the highest quartile exhibited a higher risk (Hazard Ratio [HR] = 2.15; 95% Confidence Interval [CI]: 1.47-3.12). Higher AIP also correlated with faster memory decline (β = -0.14, 95% CI: -0.26 to -0.01). Participants with higher AIP and elevated p-tau181 had an increased risk of cognitive impairment (HR = 3.46, 95% CI: 1.58-7.61). These effects were more pronounced among APOE ε4 carriers. CONCLUSIONS: Higher AIP was associated with cognitive impairment and faster memory decline. High AIP combined with elevated p-tau181 was associated with greater risk, particularly among APOE ε4 carriers, supporting refined risk stratification in older adults.

Neuroepidemiology
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon